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Abstract 
 
Introduction 
Drug emission from DPIs is dependent on the inspiratory flow parameters through them, 
which are not directly measured by standard spirometry. Their estimation based on native 
spirometric data could help in choosing the appropriate device and optimizing the drug 
deposition. 
Objectives 
The aim of this study was to survey patient preferences and to find correlations between 
breathing parameters of COPD patients through DPI devices and their baseline spirometric 
data, age, gender, disease severity and anthropometric characteristics. Another objective was 
to establish relationships between peak inspiratory flows (PIFdev) through Breezhaler
®, 
Genuair® and Turbuhaler® inhalers and their determinants. 
Methods 
Breathing parameters of 49 patients with previously diagnosed COPD and currently using 
one of the above inhalers were recorded by normal spirometry and while inhaling through the 
selected DPIs. Statistical analysis of the measured data was completed. All specific data are 
provided as (mean ± standard deviation). 
Results 
More than 60% of the patients stated that their current device is the easiest to use. The 
means of the measured PIFdev values were 91.4 L/min, 77.1 L/min and 77.5 L/min for 
Breezhaler®, Genuair®, and Turbuhaler®, respectively. PIFdev were significantly higher for 
males than for females, but differences upon age, BMI and disease severity group were not 
significant (at p=0.05). Peak inspiratory flows through the inhalers (PIFdev) correlated best 
with their native spirometric counterparts (PIF) and linear PIFdev-PIF relationships could be 
determined (Breezhaler®: r=0.60, p=0.002, Genuair®: r=0.55, p=0.001, Turbuhaler®: r=0.57, 
p=0.002). Physical background of the deduced equations was also provided. 
Conclusions 
Present correlations may be used to assess the success of inhalation of COPD patients 
through the studied devices and to choose the appropriate device for each patient. As a 
consequence, the amount of the drug emitted by the device can be optimized, the deposition 
efficiency within the lungs increased and the related therapeutic effect improved. 
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Introduction 
Aerosol drugs play a key role in the treatment of airway diseases, especially asthma and 
COPD. Due to the rise in the number of asthmatics and COPD patients the market for aerosol 
drugs is also increasing. This expansion triggers intensive drug and device developments. The 
release of bicomponent, and recently even tricomponent fixed combination drugs further 
enhanced the number of available device-drug pairs. In addition, concomitant with the 
expiration of several original drug licences in the last couple of years an increasing number of 
generic aerosol drugs are being introduced into the market. Due to the high and continuously 
enhancing number of available device-drug combinations and admitting that every patient is 
different (physical and mental capacity, disease type and severity etc.), it is more and more 
difficult to choose the right device and medication for each patient. The absence of an ‘ideal 
device’ and the difficulties in choosing the ‘right device’ has been recognized also by major 
respiratory societies (European Respiratory Society, International Society for Aerosols in 
Medicine, American Thoracic Society), who are trying to formulate principles and 
recommendations in this field [1]. Besides cognitive ability and dexterity of the patients 
inhalation characteristics should be a major determinant of device selection. Due to the broad 
spectrum of available devices even in the case of pressurized metered dose inhalers (pMDIs), 
where the emitted dose and aerosol particle characteristics are not functions of the patient’s 
breathing capabilities, the selection of the drug and device providing optimal lung deposition 
is not a trivial task. The situation becomes even more complicated in the case of dry powder 
inhalers (DPIs). The emitted amount of drug and the detachment of active pharmaceutical 
ingredients (APIs) from the carriers can be highly influenced by the breathing parameters of 
the patients [2]. Weak inhalation force of the patient may lead to low emitted dose, 
insufficient API detachment and poor therapeutic outcome. Although lung function data is 
usually available at the moment of drug prescription, how these data convert into breathing 
performance through different DPIs is far from trivial. In practice, the breathing parameter 
values that a patient would produce through different inhalation devices are not available to 
the doctor and it is practically not possible to acquire them for each patient and device due to 
several reasons, such as technical difficulties, consultation time constrains and so on. It is 
worth noting that the In-Check/In-Check Dial device (Clement Clarke International) may 
partly overcome this problem and also serve as a training tool. Based on the studies available 
in the open literature this peak flow meter proved to be both useful and reliable [3]. However, 
the device is not available everywhere, requires the cooperation of the patient, does not 
include all the inhalers available on the market (although the latest version contains many of 
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them and classes of devices upon resistance ranges have been introduced) and still requires 
some time to perform the flow measurements. In addition, the device does not provide 
information on other predictors of inhaler usage or lung deposition. Among other 
developments in the field of patient breathing capability assessment and training tools it is 
worth noting Vitalograph’s Aerosol Inhalation Monitor AIMTM [4] and the Inhalation 
Manager [5], [6]. These tools are restricted to a limited number of DPI devices: one medium 
resistance virtual DPI in the case of AIMTM and five real DPIs (Diskus®, Turbuhaler® at the 
beginning, then extended with Easi-Breathe®, Novolizer® and Spiromax®) in the case of 
Inhalation Manager. 
An alternative way of assessing patient’s breathing capabilities through different DPIs 
would be to find statistically significant correlations between relevant breathing parameters 
through different DPIs and native lung function data. If reasonable, these functions could be 
established separately for different subgroups of populations upon certain demographic 
indicators or based on disease types and disease severity classes. A software linked to the 
outputs of lung function tests using the relationships between device specific and baseline 
spirometric breathing parameter values for several devices could then instantly predict the 
ability of a given patient to appropriately inhale through different DPI devices. Such a tool 
may assist medical practitioners at least in excluding some devices, but hopefully also in 
choosing the most appropriate device-drug pair. There is only a limited number of studies in 
the open literature following this approach. The subjects of these studies were patients with 
different lung diseases (COPD, asthma, neuromuscular disease) using Turbuhaler® [7-9]. 
Diskus®/Accuhaler® [7-9], [10], Easyhaler® [11] and Aerolizer® [7] DPIs. In these studies the 
main emphasis was put on finding correlations between different spirometric, demographic 
and anthropometric parameters, however, with the exception of the work of Kawamatawong 
et al. [9] and to some extent Seheult et al. [10] the possibility of making predictions related to 
correct inhaler use of patients who did not participate in the study based on the analysed data 
was not explored. 
The general scope of our work was to measure and analyse baseline spirometric data and 
device specific breathing parameters of COPD patients for three different commercialized 
DPIs. We aimed to establish relationships between the two groups of parameters with 
predictive power regarding inhaler suitability. The special goal of this study was to establish 
the conditions for exceeding the device-specific minimum flow rate thresholds. 
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Methods 
The experimental measurements of the present study were performed at the Pulmonology 
Department of Petz Aladár County Teaching Hospital (Győr, Hungary) based on the protocol 
approved by the Regional Science and Ethics Committee (approval number: 76-1-20/2017). 
Forty-nine adult patients (21 females and 28 males) with previously diagnosed COPD of 
different severity degrees (GOLD grade B, C and D) were recruited. Written consent was 
obtained from all participants. The patients were on medication in the period preceding the 
measurements (for at least 3 months) taking aerosol drugs emitted by one of the Breezhaler®, 
Genuair® or Turbuhaler® DPIs. The only exclusion criterion was the capacity of the patients 
to comply with the instructions. Patient baseline lung function variables were recorded. Table 
1 summarizes these data in addition to patient demographics. 
Table 1. Summary of patient demographics and baseline lung function data. Mean values 
with standard deviations (first row) and ranges (second row) for the population of 49 patients 
are provided. BMI – body mass index; FEV1 - expiratory volume at the end of the first second 
of forced exhalation; FVC – forced vital capacity; PIF – peak inhalation flow; IVC – 
inspiratory vital capacity 
Age 
(years) 
Gender 
(F:M %) 
BMI 
(kg/m2) 
FEV1 
(L) 
FEV1 
(%) 
FVC 
(L) 
FVC 
(%) 
FEV1/FVC 
(%) 
PIF 
(L/min) 
 
IVC 
(L) 
65.7±6.9 
48-87 
42.9:57.1 27.1±6.5 
16-50.7 
1.4 ±0.6 
0.5-3.4 
50.6 ±16.7 
25-86 
2.0±0.9 
0.4-4.9 
70.1±17.6 
39-107 
56.7±9.9 
36.3-69.8 
143.1±71.9 
31.2-358.8 
2.4 ±0.8 
1.1-4.9 
 
 
Breathing parameters of the same patients were also documented while they used the 
above three inhalation devices by Otthon IdegenTM Mobile Handheld Spirometer of Thor 
Laboratories (Budapest, Hungary), which was connected to the DPIs (between the patient and 
the inhaler). Patients were instructed on the use of the devices in accordance with the patient 
information leaflets. The order of the devices used in the inhalation experiments was 
randomized among the patients. Original inhalation devices were used to ensure realistic 
airflow resistances. However, the DPIs were emptied from the drugs to make sure that no 
active substance is inhaled by the patients during the experimental measurements. After 
inhaling through the devices patients were asked to provide an order among the devices based 
on their subjective preference and on how easy it was to inhale through them. 
The spirometer was validated before the measurements on the patients by the connection of 
each device to a pump providing constant flow rates of 30, 60, 90, 120 and 150 L/min. The 
flow may become unstable to some extent after passing through the inhalers depending on the 
inhaler internal resistance and geometry. This may induce some uncertainty of the measured 
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flow rate. In this work, the degree of flow instability was quantified for each device by 
recording the flow rate with the spirometer connected to the exit of the devices during 10 s, 
three times for each of the above flow rates. The shape of the curves was statistically analysed 
and the fluctuations characterized by the calculation of the relative standard deviations of the 
flow rate. The experimental setup used for this purpose can be seen in Figure 1. 
 
Figure 1. Experimental setup for the validation of the spirometer 
The key breathing parameter predicting the ability of the patient to optimally use the 
device is peak inspiratory flow through the device (PIFdev). The dose emitted by a DPI, the 
amount of drug containing particles with aerodynamic diameter smaller than 5 m and 
implicitly the fraction of dose depositing within the lungs are influenced by this parameter. 
Minimum requirements in terms of patient inhalation flow rate have been established in the 
open literature for each of the studied devices. Based on the work of Haidl et al [12] these 
thresholds are 50 L/min for Breezhaler®, 40 L/min for Genuair® and 30 L/min for 
Turbuhaler®. By the same token, it was reported by several investigators [13-14] that between 
30 L/min and 60 L/min the inhalation from Turbuhaler® is suboptimal, thus 60 L/min is a 
second threshold for this DPI. The analysis of the dependence of PIFdev for each selected 
device on patient demographic data (age, gender), anthropomorphic characteristics (height, 
weight), disease condition (expiratory volume at the end of the first second of forced 
exhalation: FEV1, forced vital capacity: FVC, Tiffeneau index: FEV1/FVC, GOLD grades), 
smoking habits (pack years) and baseline spirometric data characterizing the inhalation (peak 
inspiratory flow: PIF, inspiratory vital capacity: IVC, inhalation time: tin) was performed by 
an in-depth statistical evaluation of the inter-relationships. Cross-correlation analysis of the 
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above parameters (except gender, and GOLD grades) in connection with each device was 
performed. Correlations between different parameters were expressed by Pearson coefficients. 
Predictors of PIFdev were found by stepwise multiple regression analysis using a backward 
elimination technique. 
Mean PIFdev values of different patient subgroups upon gender, age, body mass index 
(BMI) and disease stages (GOLD grades) were analysed by conducting two-sample t-tests. 
Two age groups were formed. The cut-off age was 65 years, because most of the developed 
countries have accepted the chronological age of 65 years as a definition of 'elderly' or older 
person. By the same token, two groups were formed upon BMI by using a cut-off value of 
25 kg/m2. Another meaningful cut-off value would be at 18.5 kg/m2, however, only two 
patients of this study would be in the lowest BMI group, thus this division was ignored. Two 
groups were analysed also based on disease severity. The first group (GOLD B) included 26 
patients and the second group (GOLD C and D) 23 patients. 
All statistical analyses have been performed by the application of OriginPro 2018 (version 
b9.5.0.193, OriginLab Corporation, Northampton, Massachusetts, USA) and Minitab® 
(version 18.1, Minitab, Inc., State College, Pennsylvania, USA) software packages. A value 
of p<0.05 was considered significant throughout the study. 
 
Results 
Flow rate uncertainty 
As mentioned in the Methods section, the presence of DPIs causes some flow disturbance 
next to the inhaler exit and inherent uncertainties in the flow rate measurements. Figure 2 
(upper panel) depicts an example of the fluctuating flow downstream the inhaler 
(Turbuhaler®) at 60 L/min pump flow rate. Recording and analysing similar plots for 
Breezhaler® and Genuair® at 30, 60, 90, 120 and 150 L/min (rounded values) pump flow rates 
gave us the possibility to compute the relative standard deviations, which are depicted in 
Figure 2 (middle panel). As the figure demonstrates, the uncertainty is device and flow rate 
dependent. Higher inhalation flow rates are associated with higher uncertainties, but for the 
same flow rate the uncertainty is the highest for Genuair®, followed by Turbuhaler® and 
Breezhaler®. It is worth noting that this uncertainty does not affect all inhalation parameters. 
It is relevant only in the determination of peak inspiratory flow (PIFdev), but it does not 
influence the inhalation time and breath-hold time. The inhaled volume (IV) can be 
determined as the integral of the flow-rate versus time inhalation curve (the area below the 
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inhalation curve). Since fluctuations are with equal probability up and down of the mean 
value, the area is not affected by them (see the example in Figure 2, bottom panel). 
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Figure 2. Upper panel: Flow rate through Turbuhaler® measured in vitro at 60 L/min constant 
pump flow rate (only the first 3 seconds are demonstrated); middle panel: Flow rate 
uncertainties through Breezhaler®, Genuair® and Turbuhaler® as a function of pump flow rate; 
bottom panel: In vivo measured sample inhalation profile through Turbuhaler® 
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Basic statistics of the measured breathing parameter values 
Mean values, standard deviations and ranges of the measured device specific breathing 
data are presented in Table 2. The mean values of the measured PIFdev were 91.4 L/min, 77.1 
L/min and 77.5 L/min for Breezhaler®, Genuair®, and Turbuhaler®, respectively. As the 
measured values demonstrate, the highest mean peak flow rate was observed for the device 
with the lowest reported flow resistance (Breezhaler®). At the same time, mean PIFdev through 
Genuair® was somewhat lower than through Turbuhaler®, though the resistance of Genuair® 
is slightly lower than that of Turbuhaler®. This suggests that besides flow resistance, other 
factors may also affect to some extent the usage of DPI inhalers and the resulting peak flow 
rate (human factors). Based on Table 2 the mean values of the inhaled air volumes through the 
three devices were quite similar (1.9 L through Breezhaler® and 1.8 L through Genuair® and 
Turbuhaler®). 
The results of the two-sample t-tests on different patient groups are summarized in Table 3. 
The statistical analysis revealed that PIFdev values were significantly higher for males than for 
females for all devices. Although mean PIFdev values were systematically higher for the 
younger group, the differences were statistically not significant (at p=0.05 level). Similarly, 
there were no significant differences in mean PIFdev values between BMI groups. There was 
no significant difference in mean device-specific peak flows between the two patient groups 
classified upon disease severity, though PIFdev of the more severe COPD group was lower for 
all devices. Patients with more elevated stage of COPD (GOLD C and D) performed about the 
same when inhaled through Genuair® and Turbuhaler® (Table 3), while patients from the 
other group (GOLD B) performed much better through Turbuhaler®, being thus the subgroup 
responsible for the above mentioned observation (higher mean peak flow rate through the 
device with slightly lower flow resistance) 
Table 2. Summary of measured breathing parameter values through Breezhaler®, Genuair® 
and Turbuhaler® DPIs. Mean values with standard deviations (first row) and ranges (second 
row) for the population of 49 patients are provided. PIFdev – peak inspiratory flow while 
inhaling through the device; IV – volume of air inhaled through the device 
 
 
Breezhaler® 
PIFdev 
(L/min) 
Genuair® 
 
 
Turbuhaler® 
 
 
Breezhaler® 
IVdev 
(L) 
Genuair® 
 
 
Turbuhaler® 
91.4±32.5 
49.6-169.8 
75.1±24.2 
28.4-119.4 
77.5±30.4 
31.8-130.8 
1.9±0.7 
0.6-3.7 
1.8±0.7 
0.9-3.9 
1.8±0.7 
0.7-4.0 
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Table 3. Results of t-tests on mean inspiratory peak flow rates through Breezhaler®, Genuair® 
and Turbuhaler® of patients grouped upon gender, age, BMI and GOLD grades. p values are 
also provided within parentheses. ns – not significant (p>0.05) 
 Gender 
(female vs. male) 
Age 
(<65 years vs. >65 years) 
BMI 
(< 25 kg/m2 vs. >25 kg/m2) 
GOLD 
(B vs. C+D) 
mean PIFdev (L/min) 
Breezhaler® 
78.8; 101.1 
(0.02) 
98.5; 85.5 
(ns) 
95.5; 90.5 
(ns) 
95.0; 86.2 
(ns) 
mean PIFdev (L/min) 
Genuair® 
65.3; 83.1 
(0.04) 
78.5; 72.2 
(ns) 
78.2; 74.7 
(ns) 
75.4; 72.6 
(ns) 
mean PIFdev (L/min) 
Turbuhaler® 
66.6; 86.3 
(0.01) 
83.1; 73.5 
(ns) 
80.7; 76.9 
(ns) 
80.7; 72.7 
(ns) 
 
Correlation analysis 
The results of correlation analysis are summarized in Table 4. As the aim was to find the 
main predictors of PIFdev, only parameters with significant correlation with PIFdev for at least 
one of the devices are listed in the table. 
Table 4. Pearson correlation coefficients of peak inspiratory flow values through different dry 
powder inhalers (PIFdev) and standard spirometric peak inspiratory flow (PIF), inhalation time 
(tin), patient height (h), expiratory volume at the end of the first second of forced expiration 
(FEV1, in % and L) and forced vital capacity (FVC, in % and L). The corresponding p values 
are also demonstrated within parentheses. ns – not significant (p>0.05) 
 PIF 
(L/min) 
tin  
(s) 
h 
(m) 
FEV1 
(L) 
FVC 
(L) 
PIFdev (L/min) 
(Breezhaler®) 
0.60 
(0.002) 
-0.34 
(0.02) 
0.25 
(ns) 
0.31 
(0.04) 
0.36 
(0.01) 
PIFdev (L/min) 
(Genuair®) 
0.55 
(0.001) 
-0.32 
(0.03) 
0.25 
(ns) 
0.23 
(ns) 
0.24 
(ns) 
PIFdev (L/min) 
Turbuhaler® 
0.58 
(0.002) 
-0.26 
(ns) 
0.30 
(0.04) 
0.40 
(0.006) 
0.39 
(0.007) 
 
No significant correlation of PIFdev with patient age and weight, FEV1%, FVC%, FEV1/FVC, 
IVC and pack years of cigarette could be found for any of the studied devices. Conversely, 
PIFdev significantly correlated with native PIF for all the three devices. In addition, PIFdev 
correlated with tin, FEV1 (expressed in L) and FVC (expressed in L) for Breezhaler
® with tin 
for Genuair® and with h, FEV1(L) and FVC(L) for Turbuhaler
®. According to different 
classification scales described in De Muth [15] the correlation between spirometric PIF and 
PIFdev is good/moderate/substantial, while the correlations between PIFdev and tin, h, FVC(L), 
FEV1(L) (only for some inhalers) are fair/weak/low. To find out the most important 
predictor(s) of PIFdev for each device a stepwise multiple regression analysis has been 
performed with PIFdev as the independent variable and the parameters significantly correlating 
with it (see Table 4). A backward elimination scheme was applied, that is, at each step the 
independent variable with the highest p value was dropped, until only predictor(s) with 
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p<0.05 remained. Our analysis has demonstrated that the peak inspiratory flow through a 
device is best predicted by native peak inspiratory flow, which is measured during standard 
lung function tests (PIF). All the other independent variables could not be retained if the 
significance level was set to p=0.05. Figure 3 depicts the relationships between PIFdev and 
standard spirometric PIF for the three devices. 
 
 
 
Figure 3. Dependence of peak inspiratory flow (PIFdev) through Breezhaler
® (upper panel, 
r2=0.36, p=0.002), Genuair® (middle panel, r2=0.30, p=0.001) and Turbuhaler® (lower panel, 
r2=0.33, p=0.002) on the native spirometric peak inspiratory flow (PIF) based on the statistical 
analysis of the measurements on 49 COPD patients. Threshold PIFdev values are marked with 
horizontal dashed lines 
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Based on our measurement results only one patient (out of 49) was unable to generate at 
least 50 L/min peak flow rate through Breezhaler® (two others only slightly exceeded 50 
L/min), 8 individuals failed to reach 40 L/min through Genuair® and all patients had PIFdev 
higher than 30 L/min through Turbuhaler®, but 22 subjects did not exceed 60 L/min through 
this device (see Figure 3). Present regression analysis results can be used also to predict the 
chances that a patient with known spirometric PIF will exceed the threshold flow rate when 
she/he inhales through a DPI. Figure 4 demonstrates the probability curves for Breezhaler® 
(threshold flow rate = 50 L/min), Genuair® (threshold = 40 L/min) and Turbuhaler® (with 30 
L/min and 60 L/min thresholds). Based on the statistical results depicted in Figure 4, we can 
be 95% confident that a patient inhaling through Turbuhaler® will exceed 30 L/min if her/his 
native PIF reaches 135 L/min. The 60 L/min threshold through the same inhaler requires 295 
L/min standard spirometric PIF. Similarly, at 95% confidence level the 50 L/min 
(Breezhaler®) and 40 L/min (Genuair®) threshold peak flow rates are exceeded if the patient’s 
native peak flow rate exceeds 143 L/min and 183 L/min, respectively. 
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Figure 4. Probability of exceeding device specific flow rate thresholds versus native peak 
inspiratory flow rate for Breezhaler®, Genuair® and Turbuhaler®. For Turbuhaler® both the 
minimal and optimal thresholds are considered 
 
Patient preferences 
At the time of the measurements 40.8 % of the patients under treatment used Breezhaler® 
(20 patients), 47% Genuair® (23 patients) and 12.2% Turbuhaler® (6 patients). Based on the 
results of the survey 28 patients stated that Breezhaler® was the easiest to inhale through, 9 
individuals opted for Genuair® and 12 subjects mentioned Turbuhaler®. Another important 
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outcome is that 61.2% of the patients (30 individuals) stated that they preferred their current 
device (they felt that the inhalation through their own device was the easiest), 16.3% (8 
patients) placed their actual device on the second place and 22.5% (11 subjects) on the third 
place. 
 
Discussion 
 
Connections between patient device preferences, inhalation peak flow rates through the 
devices and device flow resistances 
As noted in the Results section, the mean value of PIFdev for the whole study population 
was the highest for Breezhaler®, the device with the lowest flow resistance. However, mean 
PIFdev for Turbuhaler
® was higher than for Genuair® (77.5 L/min versus 75.1 L/min), though 
flow resistance of Turbuhaler® is slightly higher than that of Genuair® [16]. It was also shown 
that this is mostly due to patients from the less severe disease group (GOLD B, see Table 3). 
Since the order of the inhalation through the devices was randomly distributed among the 
patients and there was also sufficient time between inhalations through different devices, the 
result cannot be a bias due to fatigue. It is interesting that patient’s preferences were in line 
with the magnitude of the mean inhalation peak flow rate values through the devices: 
Breezhaler® the most preferred, followed by Turbuhaler®, then Genuair®, though the 
difference between the last two was not determinant. Present results suggest that while peak 
flows through the devices are generally inversely proportional to device resistance, other 
factors (related mostly to the patients but possibly also to the devices) may also slightly 
influence the smooth decay of PIFdev with the increase of device resistance. 
 
Relationship between device specific peak flows and age 
As presented in the results section, PIFdev failed to significantly correlate with age. This 
observation may seem to be in contradiction with some results published in the literature. 
Malmberg et al. [7], Jarvis et al. [8] and Janssens et al. [11] have found significant negative 
correlation of the peak flow of COPD patients through DPI devices with age. However, 
Janssens et al. [7] have demonstrated similar correlation for elderly healthy subjects as well 
and concluded that decline in PIFdev is due to elevated age regardless to the health status. 
Indeed both in the works of Janssens et al. [7] and Jarvis et al. [8] the subjects were much 
older than is our study (only two patients from our study attained the mean age of 76 years of 
the subjects in [7]). Separate equations for this age group with age as a predictor besides 
native PIF could not be deduced in our work because our sample was not representative in the 
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very old category (>75 years), however, this will be an important task in the future. The 
importance of extending our investigation to higher age range is also highlighted by the fact 
that subjects from this category are the most likely persons to fail in generating sufficient flow 
rate. By the inclusion of age as a second significant predictor in the regression equations their 
predictive power would also increase. 
 
On the predicting power of current results 
Based on the results in Figure 4 for each patient characterized by a spirometric PIF value a 
ranking of the devices can be performed upon the probability of exceeding the threshold flow 
rate. For instance, if a patient’s spirometric PIF is 140 L/min, then the probability of a 
satisfactory inhalation flow rate through the device is 88% for Genuair®, 94% for Breezhaler® 
and 95.5% for Turbuhaler®. There is also a 60% probability that the patient will have over 60 
L/min peak flow rate through Turbuhaler®. Unfortunately, the linear regressions in Figure 3 
explain only 36% (Breezhaler®), 30% (Genuair®) and 33% (Turbuhaler®) of the variance of 
PIFdev More data points, especially in the PIF<50 L/min and PIF>200 L/min regions, would 
enhance the statistical power. In the low PIF region this could be achieved by the inclusion of 
more subjects with elevated age (older than 75 years). In addition, using equations suggested 
by physical models or/and considering more predictors could enhance the predicting power of 
the PIFdev-PIF relationships. Some of these possibilities will be explored in the next 
paragraphs. 
 
About the physics behind the relationships in Fig. 1 
Besides rigorous statistical analysis, it is useful to explore the physical background of the 
relationship between PIFdev and spirometric PIF for different devices. In order to get insight 
into the mechanisms behind these relationships one can consider that the pressure drop over 
the respiratory system is proportional to the flow rate in the laminar flow regime and 
proportional to the square of the flow rate in the turbulent regime [17]. This observation is in 
line with the classical Rohrer’s pressure-flow relationship [18]. Since, the resistance of the 
airways is proportional also to the inverse of the volume [19], considering both the laminar 
and turbulent parts of the airways the pressure drop can be expressed as 
2
0 1 2
Q Q
p k k
V RV V RV
  
 
        (1), 
where p0 is the pressure drop through the airways without any inhaler, Q the flow rate 
through the airways, RV the residual volume and k1 and k2 constants depending on air 
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properties and airway anatomy. Similarly, considering the resistance of the airways to be 
connected in series with the resistance of the device the pressure drop developed by the 
respiratory muscles applied to this system is 
2
2
1 2 dev
Q Q
p k k k Q
V RV V RV
   
 
       (2), 
where p is the pressure drop through the airways and the inhaler and kdev the square of 
device resistance. The last term expresses the pressure-flow relationship through the DPI 
device deduced by Ower and Pankhurst [20]. Equations (1) and (2) are valid at any moment of 
the inhalation, thus also for the peaks of the inhalation curves without and with the device 
(PIF and PIFdev). Obviously, the value of airway volume corresponding to the two peak flows 
(with device and without it) will be different. Assuming that the patient applies the same 
forceful inhalation manoeuvre with and without the device, the pressure drop through the 
airways at peak inspiratory flow without the inhaler equals the pressure drop through the 
airways and the inhaler at peak flow (pA=pB). Denoting the corresponding airway volumes 
by V0 and V equations (1) and (2) yield 
2 2
2dev dev
1 2 1 2 dev dev
0 0
PIF PIF PIF PIF
k k k k k PIF
V RV V RV V RV V RV
   
   
    (3) 
The solution of the above second order equation (in PIFdev) is proportional to 
2
1 21 1 h PIF h PIF     , where h1 and h2 are functions of k1, k2, kdev, VR, V0 and V. 
Performing nonlinear fit of the measured PIF values to this expression we get (h1, h2) sets of 
(66.858, -0.040), (32.967, 0.015) and (33.750, -0.011) for Breezhaler®, Genuair® and 
Turbuhaler®, respectively. Figure 5 demonstrates the fitted curve for Turbuhaler® (continuous 
curve) in comparison with the linear fit (dashed line). As it can be seen, the physical model is 
not very different from the linear model, except below PIF=100 L/min. In this low flow rate 
region the non-linear fit may be more realistic also because it satisfies the PIFdev(0) = 0 
condition, which is not the case for the linear model applied in Figure 3. However, none of the 
curves can provide predictions outside the interval of the measured PIF values. It is also worth 
noting however, that purely statistically the physical model is not a better fit of the measured 
data (standard errors of the two fits are about the same). 
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Figure 5. Comparison of physical and linear models for the prediction of peak flow through 
the device (PIFdev) in the case of Turbuhaler
® 
 
On the inclusion of native PEF as a predictor of PIFdev 
In some studies [9], [11] peak expiratory flow of standard lung function measurements 
(PEF) was included as a predictor of peak inspiratory flow through the device (PIFdev). 
Although intuitively inhalation parameters should be better predictors of PIFdev than 
expiratory ones, there might be some explanation supporting the inclusion of PEF as well (e.g. 
both PIFdev and PEF are measured at maximum effort of more or less the same muscles of the 
same person). The consideration of PEF is further supported by the significant and relatively 
good correlation between PEF and PIFdev (Pearson coefficients of 0.34 for Breezhaler
®, 0.33 
for Genuair® and 0.41 for Turbuhaler®). However, repeating the multiple regression analyses 
with the inclusion of PEF as one of the independent variables revealed that PEF could not be 
retained as a predictor of PIFdev for Breezhaler
®, Genuair® or Turbuhaler®. 
 
Outlook 
Fitting parameters h1 and h2 of the physical model in Figure 5 are functions of device 
resistance, airway residual volume and airway volume and resistance at peak flow. While 
device resistance is a constant, airway resistances and volumes could be predictors of PIFdev. 
However, residual volume and airway resistance were not measured with the handheld 
spirometer. It would be useful to measure them during future similar works and analyse their 
correlation with PIFdev. 
It was demonstrated by several investigators [21], [22] that besides the peak flow rate 
(PIFdev) the dose emitted by DPIs, the size distribution of the emitted particles and 
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consequently airway deposition distribution also depend on the inhaled air volume through 
the device (IVdev) and also on airflow acceleration characterized by the time necessary for the 
flow rate to reach its maximum (flow rump-up time, tac-dev). In addition, the amount (dose) of 
drug depositing in different regions of the airways depends on additional breathing 
parameters, such as the inhalation time (tin-dev) and breath-hold time (tb-h) after the inhalation 
[23]. Finding the main predictors of these parameters could help us in better predicting airway 
deposition distributions as criteria for appropriate device choice. 
 
Conclusions 
Present study has demonstrated that measuring breathing parameters of COPD patients by 
standard spirometry and when they inhale through different DPI devices may lead to 
statistical relationships helping the choice of the appropriate device. Moreover, the predictions 
on the success of inhalation through a given device can be provided not only for the subjects 
participating in the study, but practically for any COPD patient whose demographic and 
standard spirometric data are available and fit in the interval of corresponding data of the 
study population. It is considered that the most relevant parameter related to the amount of 
drug emitted by a DPI and to the detachment of drug particles from their carriers is the peak 
inspiratory flow through the device (PIFdev). Based on the results of the present work, the 
most important predictor of PIFdev is the baseline peak inspiratory flow (PIF). The linear 
relationship between the two quantities is supported by physical laws related to the mechanics 
of breathing, at least in the interval of 100-350 L/min spirometric PIF. To enhance the 
statistical power of the current results larger populations, especially at the lower end of PIF 
values, would be needed. In addition, accounting for airway resistance and residual volume 
could also enhance the predictive power of the established relationships. 
Statistically powerful relationships between native spirometric flow parameters and the 
corresponding quantitites through different DPIs may help the professionals to choose an 
appropriate device for each patient taking into account the patient’s breathing capabilities. As 
a result, the dose emitted by the chosen device will be high and the detachment of drug 
particles from their carriers will be efficient. This may also lead to sufficiently high fraction 
of particles able to penetrate into the lungs and deposit with high efficiency, reaching the 
receptors and developing an efficient thrapeutical effect. 
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